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Pulmonary pathology in patients with ulcerative colitis treated 
with mesalazine — a challenging and complex diagnostic 
problem. Case series and literature review
Choroba płuc u pacjentów z wrzodziejącym zapaleniem jelita grubego leczonych 
mesalazyną — trudny problem diagnostyczny. Seria przypadków i przegląd literatury
The authors declare no financial disclosure
Abstract
Pulmonary involvement in the course of inflammatory bowel disease has been a subject of  interest to clinicians for long time, but 
despite this, its epidemiology and potential pathomechanisms remain obscured. Equally unclear is the role of medications used for 
bowel disease treatment in lung disease development. We present three patients with ulcerative colitis, all treated with mesalazi-
ne, in whom unexplained lung disease developed. Due to different clinical and radiological presentation, different conditions were 
initially placed on the top of the differential list in each of them. The outcome was favourable in all patients despite differences in 
management. We compared our patients with similar cases from literature. We show the level of difficulty and complexity in the 
issue of lung disease in patients with inflammatory bowel disease.
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Streszczenie
Zagadnienie zajęcia płuc w przebiegu nieswoistych zapaleń jelit pozostaje  przedmiotem zainteresowania klinicystów od dawna. 
Pomimo to epidemiologia tego zjawiska ani potencjalne patomechanizmy nie są znane. Niewyjaśniona jest także rola leków sto-
sowanych w zapaleniach jelit w rozwoju patologii płucnej. W pracy przedstawiono troje pacjentów z wrzodziejącym zapaleniem 
jelita grubego leczonych mesalazyną, u których rozwinęła się choroba płuc. Z powodu różnej prezentacji klinicznej i radiologicznej, 
wstępna diagnostyka u każdego z nich ukierunkowana była na inne jednostki chorobowe. Zastosowane postępowanie u każdego 
z nich również było inne. Dokonaliśmy porównania naszych pacjentów do podobnych przypadków opisanych w literaturze. Opisani 
przez nas pacjenci dobrze obrazują, jak trudne i złożone jest zagadnienie chorób płuc rozwijających się u pacjentów z nieswoistymi 
zapaleniami jelit. 
Słowa kluczowe: nieswoiste zapalenia jelit, wrzodziejące zapalenie jelita grubego, mesalazyna, choroba płuc
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Introduction
Ulcerative colitis (UC), Crohn’s disease and 
a subgroup of colitis difficult to classify consti-
tute a group of inflammatory conditions called 
inflammatory bowel disease (IBD) [1, 2]. Nowa-
days, IBD is considered to be a systemic rather 
than exclusively gastrointestinal disorder. This 
is a consequence of the vast burden of informa-
tion on so-called extraintestinal manifestations 
of IBD [3–6]. There is a common belief shared 
by gastroenterologists and chest physicians that 
the lungs are, although rarely, one of the targeted 
organs in IBD. It is, however, based on clinicians’ 
observations only. Unfortunately, no proper 
epidemiological investigations have ever been 
conducted to prove it, so the subject remains 
controversial. Storch et al. [7] have summarised 
more than 400 cases of pulmonary manifestations 
of IBD, published over a period of 50 years. Here, 
we enrich the literature on that subject by adding 
three more cases that support the hypothesis of 
a connection between IBD and pulmonary patho-
logy, and show the complexity of the issue.
Case reports
Case 1
A 26-year-old, never-smoking, working as 
a shop assistant, Caucasian woman with UC was 
referred to our centre due to respiratory symp-
toms and abnormal findings in chest imaging 
studies. UC was diagnosed one year earlier. It 
had been treated with a three-month course of 
systemic glucocorticosteroids (GCs) at the begin-
ning, and with oral mesalazine in a daily dose of 
2.0 g for the last 8 months.
At the time of referral to our unit the bowel 
disease had been exacerbated for three months 
and dry cough, left-sided pleural chest pain and 
low-grade fever had been present for a month. 
Computed tomography (CT) of the chest per-
formed 10 days before the admission showed 
multiple nodules and irregular masses scattered 
bilaterally in the lungs, thickening of the pleura 
and traces of fluid in the left pleural cavity; lymph 
nodes and remaining structures of the chest were 
normal. On admission she was apyrexial, and 
physical examination revealed pale skin, body 
mass index (BMI) 22.8, heart rate (HR) 100 beats 
per minute (bpm), blood pressure (BP) 130/65 mm 
Hg, respiratory rate (RR) 16/min, oxygen satura-
tion (SaO2) 99%, no enlarged peripheral lymph 
nodes, no peripheral oedema and no abnorma-
lities on chest auscultation or abdomen palpation. 
Blood tests showed leucocytosis 14.15 × 109/L 
with neutrophilia  12.05 × 109/L ; eosinophils 
(eo) were normal. Erythrocyte sedimentation 
rate (ESR) was 115 mm/h, C-reactive protein 
(CRP) 63.4 mg/L (normal limit < 10), antinuclear 
antibody (ANA) titre 1:640 and anti-neutrophil 
cytoplasmic antibody (ANCA) negative. Renal and 
liver parameters as well as arterialised blood gases 
were normal. Chest X-ray (Fig. 1a) showed round
-shaped shadows, the largest having a diameter of 
33 mm localised in the lower field of the left lung, 
and features of fluid presence in both pleural ca-
vities. The radiologic features, especially on CT 
scans, were suggestive of an inflammatory cha-
racter of the changes, including bacterial, fungal 
and tuberculosis infection, but could also be seen 
in haematological malignancies. There were no 
abnormalities within the airways in a bronchofi-
beroscopy; bronchial secretions were obtained for 
a broad spectrum of tests. Following this initial 
work-up the patient was given a 10-day course 
of an empirical antibiotic therapy (levofloxacin 
500 mg bd orally). It resulted in normalisation of 
WBC (9.3 × 109/L), but other inflammatory indi-
ces remained significantly increased (CRP 54.6 
mg/L and ESR 120 mm/h). Microbiological and 
mycological cultures as well as tuberculosis tests 
(microscopic study, genetic probe) of bronchial 
secretions were negative and the cytology was 
irrelevant. There was no improvement on chest 
X-ray, and follow-up CT scanning (Fig. 1b) of 
the chest showed increase of the size of nodules 
when compared to a study performed one month 
earlier. At that stage a histological verification 
was required. The patient underwent left-sided 
video-assisted thoracoscopy with resection of 
the mass from the left lower lobe. A microscopic 
examination revealed confluent active inflamma-
tion of the type of organising pneumonia with 
eosinophilic infiltrates, which in the opinion of 
the histopathologist could have been either as-
sociated with inflammatory bowel disease itself 
or drug (mesalazine) — induced. The cessation 
of mesalazine and treatment with systemic GCs 
were intended. The patient, however, declined 
the offered management and decided to continue 
to take mesalazine. 
At a 3-months follow-up visit her condition 
was significantly improved, symptoms relating 
to the respiratory system disappeared. She still 
suffered from intestine-related problems. Blood 
tests were within normal limits. Chest X-ray 
revealed the regression of changes seen before, 
with only residual linear scars in the lower zone 
of the left lung. Pulmonary function tests showed 
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Figure 1. Case 1; A — chest x-ray; B — HRCT scans show multiple nodular opacities, more extensive in the left lower lobe
normal values of volumes and DLCO remained at 
the level of 70% of predicted.
Case 2
A 31-year-old, never-smoking, working in 
an office Caucasian man with UC diagnosed five 
years earlier, treated for this reason with oral and 
rectal preparations of mesalazine, having featu-
res of mild exacerbation of the intestinal disease 
for the last few days, presented with dry cough, 
right-sided chest pains of pleural type and fever. 
The symptoms had been present for 3 weeks and 
had not responded to an antibiotic and inhaled 
bronchodilators prescribed by his GP. Chest X-ray 
performed two weeks after the onset of the disease 
showed subpleural opacities in the middle/lower 
field of the right lung. Chest X-ray repeated one 
week later (Fig. 2a) revealed progression of these 
abnormalities.
The patient’s condition at the time of admis-
sion to the hospital was fair; he was apyrexial but 
suffering from oppressive dry cough and pleural 
pain. Physical examination revealed BMI 23, 
HR 98 bpm, BP 140/90 mm Hg, RR 18/min, SaO2 
97%, peripheral lymph nodes were not enlarged 
and peripheral oedema was not present. Normal 
vesicular breathing sound was heard on chest 
auscultation; however, it was slightly reduced 
at the base of the right lung. Blood tests were 
as follows: WBC 16.47 × 109/L, neu 9.9 × 109/L, 
eo 2.24 × 109/L, ESR 80 mm/h, CRP 27.5 mg/L, 
ANA titre 1:160 and ANCA negative. Renal and 
liver parameters as well as arterialised blood 
gases were normal. Pulmonary angiography CT 
(Fig. 2b) was performed because a pulmonary 
embolism was one of the differential diagnoses. 
No contrast filling defects within the pulmonary 
artery bed were found. However, the lung win-
dow of the CT study showed multiple subpleural 
parenchymal consolidations in the right lung. No 
mediastinal lymphadenopathy or pleural fluid 
was seen.  Localisation and morphology of lung 
abnormalities were highly suggestive of organi-
sing pneumonia. Bronchofiberoscopy was carried 
out showing normal airways. Bronchoalveolar 
lavage (BAL) was performed, and immunological 
cell differential was as follows: macrophages — 
80.5% (normal > 90%), lymphocytes — 13.5% 
(normal < 10%), neutrophils — 5.5% (normal 
< 3%), eosinophils — 0.5% (normal  < 0.5%). 
Lymphocyte CD4+/CD8+ ratio was 2.74 (nor-
mal range 1.5–2.5).  Other results of BAL fluid 
examination, i.e. microbiological cultures and 
cytology, were not relevant. Due to the patient’s 
cough and a characteristic picture of CT findings, 
transbronchial lung biopsy was considered not 
only unsafe but also unnecessary. Based on clini-
cal and radiological presentation, high eosinophil 
count in peripheral blood, coexistence of UC 
and mesalazine intake, a diagnosis of organising 
pneumonia associated with either inflammatory 
bowel disease or, more probably, with mesala-
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Figure 2. Case 2; A — chest x-ray; B — chest CT scans show multiple 
subpleural consolidations in the right lung
zine toxicity was established. Mesalazine was 
stopped and treatment with oral prednisone 50 
mg a day (0.6 mg/kg of body weight) and inhaled 
ciclesonide 320 micrograms bd (to relieve severe 
cough) was commenced. It resulted in an rapid 
improvement of the symptoms, normalisation 
of blood eosinophils count within three days, 
and partial resolution of changes on chest x-ray 
seen after one week of the treatment. The dose of 
prednisone was slowly reduced to 30 mg a day 
and the patient was seen again three months later. 
He was in good condition, free of any respiratory 
symptoms. Inflammatory indices were not eleva-
ted: ERS 5 mm/h, CRP < 5 mg/L. WBC was 11.29 
× 109/L and eosinophils count was 0.15 × 109/L. 
High resolution CT (HRCT) of the lungs showed 
complete regression of parenchymal lesions. Pul-
monary function tests (not performed previously 
due to oppressive cough) showed: FEV1 103% of 
predicted value (pred), VC 104% of pred, FEV1/ 
/VC 0.84, RV 148% of pred, TLC 113% of pred, 
RV/TLC 0.31, DLCO 84% of pred. The patient was 
recommended to continue treatment with pred-
nisone in decreasing doses until final withdrawal 
within another three months. 
Case 3
A 65-year-old, retired, never-smoking Cauca-
sian woman with UC was admitted to our Depart-
ment due to respiratory symptoms and abnormal 
findings in imaging studies of the chest. UC had 
been diagnosed 2.5 years earlier. It had been 
treated with prednisone for a short initial period 
and, subsequently, with oral mesalazine for many 
months. The patient noticed exertional breath-
lessness one year prior to admission, but for the 
last six months it had been more troublesome. 
Sweating and body weight loss, 8 kg in total, also 
occurred. The patient’s daughter had pulmonary 
tuberculosis a couple of years earlier. For these 
reasons chest CT examination was carried out 
and it showed inhomogeneous attenuation of 
the lung parenchyma with irregularly scattered 
subtle interstitial patchy opacities, especially 
in the upper lobes and superior segment of the 
right lower lobe. At the time of exaggeration of 
respiratory symptoms, UC became active, too. 
Shortly after the aforementioned chest CT was 
performed, the patient was admitted to a gastro-
enterology department, where oral prednisone in 
a starting dose of 60 mg a day and 6-mercapto-
purine were added to the treatment. It resulted 
in improvement of both bowel and respiratory 
symptoms. 
The patient presented to our unit three weeks 
after discharge from the gastroenterology de-
partment. She continued on prednisone (55 mg/ 
/day), 6-mercaptopurine and oral mesalazine 3 g/ 
/day. Her exertional breathlessness was improved 
and she was free of intestinal symptoms. She 
had normal body temperature, BMI 27.6, HR 84 
bpm, BP 130/80 mmHg, RR 16/min, SaO2 96%, no 
enlarged peripheral lymph nodes, no peripheral 
oedema and no abnormalities on chest auscul-
tation or abdomen palpation. Blood cell count, 
renal and liver parameters and arterialised blood 
gases were normal. ESR was 11 mm/h, CRP 6.3 
mg/L, ANA titre 1:100 and cANCA was positive 
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in titre 1:40. There were no significant alterations 
in chest X-ray. CT scan showed partial regression 
of previously seen diffuse interstitial abnorma-
lities, subtle centrilobular nodules were still 
present in the upper lobes (Fig. 3). Pulmonary 
function tests revealed irreversible mild airway 
obstruction and hyperinflation of the lungs (FEV1 
78% of predicted, VC 115% of predicted, FEV1/ 
/VC 0.65, RV 170% of predicted, TLC 129% of 
predicted and RV/TLC 0.56 ) with normal DLCO 
(75% of predicted). BAL fluid differential count 
was as follows: macrophages 58.1%, lymphocytes 
39.4%, neutrophils 2.5% and eosinophils 0.0%. 
Lymphocyte CD4+/CD8+ ratio was 3.4. Trans-
bronchial lung biopsy was planned but could not 
be performed due to the patient’s poor coopera-
tion. Microscopic examination of BAL fluid for 
acid-fast bacilli was negative, but the genetic 
probe was positive. The culture was ultimately 
inconclusive as it was contaminated. Blood 
T-SPOT TB test yielded a negative result. This 
fact and the significant clinical and radiological 
improvement on prednisone therapy were clear 
evidence against infectious aetiology, including 
tuberculosis. A watchful waiting attitude was 
adopted and the patient was recommended to 
continue with treatment according to the plan 
of the gastroenterologists in charge. She has 
been seen in our Department twice since then. 
During one-year follow-up she remained free of 
respiratory symptoms, her chest X-ray stayed 
stable and DLCO fluctuated slightly around 70% 
of predicted. The respiratory symptoms did not 
recur even when prednisone was stopped and she 
continued treatment with mesalazine. 
Discussion
The differential diagnosis of pulmonary 
pathology in patients with inflammatory bowel 
disease embraces: infections, including oppor-
tunistic ones in patients taking GCs and/or other 
immunosuppressive agents, pneumonitis asso-
ciated with IBD, pulmonary complications indu-
ced by used medications, and thromboembolic 
disease. Additional considerations are related to 
the presence of ANA and/or ANCA, frequently 
seen in association with IBD [8–11]. Differen-
tiation is usually challenging, as it was in the 
presented cases. In addition, there is no specific 
marker or a single test that could differentiate 
between a coincidental pulmonary disorder and 
one potentially related to IBD or a drug-induced 
one. Establishing the ultimate diagnosis involves 
a broad set of additional investigations and a dose 
of clinician’s arbitrary opinion. 
All the presented patients suffered from 
ulcerative colitis, the diagnosis of which prece-
ded occurrence of respiratory system disease by 
one year in case 1, five years in case 2 and two 
and a half years in case 3. All had been treated 
with oral mesalazine when respiratory disease 
occurred; the duration of the treatment ranged 
from eight months (case 1) to five years (case 2). 
Patient 2 was using mesalazine rectal supposito-
ries in addition to its oral preparation. In Patient 1, 
respiratory symptoms developed one month after 
the beginning of UC flare, in Patient 2 concomi-
tantly with mild UC exacerbation, while Patient 
3 suffered from exertional breathlessness for 
several months before a flare of UC. Presentation 
A B
Figure 3. Case 3: HRCT scans  show diffuse, ill-defined nodules within both lungs
Aneta Kacprzak et al., Pulmonary pathology in patients with ulcerative colitis treated with mesalazine
373www.pneumonologia.viamedica.pl
of Patient 1 and 2 shared a lot of similarities, with 
an acute beginning and domination of cough, 
pleural chest pain and fever, whereas in Patient 
3 prolonged exertional dyspnoea, sweats and 
body weight loss were the main symptoms. All 
of them had abnormal lungs in imaging studies. 
The review of 27 published cases [12–33] of IBD 
patients (19 UC and 8 Crohn’s disease patients) 
treated with oral mesalazine, in whom lung 
disease developed, showed that presentation 
of our patients was typical. The most common 
symptoms reported in the literature included: 
exertional breathlessness (22/27 patients), fever 
(18/27 patients), cough (18/27 patients), pleu-
ritic chest pain (8/27 patients), body weight loss 
(4/27 patients) and sweats (2/27 patients). In 12 
(44%) patients a triad of breathlessness, fever 
and cough was present. The median duration 
of exposure to mesalazine was 8 months (range 
2 days — 8 years). Respiratory disease appeared in 
association with IBD flare as well as in the period 
of its quiescence. Our patients were in good/fair 
condition and had normal blood gases, but the 
literature shows that a vast proportion of similar 
patients presented with hypoxaemia of varying 
degree, some of them requiring admission to an 
intensive care unit [25, 33]. Data on imaging stu-
dies (chest X-ray, CT scanning) were given for 25 
of the reviewed patients. Bilateral changes were 
seen in 21 patients, unilateral changes (interestin-
gly right-sided in all cases) in 3 patients and in 
1 patient imaging studies were normal. The broad 
spectrum of radiological findings, from the subtle 
thickening of the interstitium through centrilobu-
lar nodules, ground glass opacities, nonspecific 
opacities (migratory in one case) to multiple pul-
monary nodules, was seen. Pleural fluid was pre-
sent in three cases. Similarly, each of our patients 
had a different radiologic pattern of the lung. In 
Case 1, bilateral nodules and pleural effusion 
were present. In Case 2, multiple subpleural 
consolidations were seen in the right lung and in 
Case 3, centrilobular nodules were present. Data 
on WBC and blood eosinophilia were available 
for 16 reviewed IBD patients. In 10 patients the 
number of eosinophils in the blood was normal. 
In 6 patients it was elevated (in one of them 
eosinophilia was present before mesalazine com-
mencement). BAL fluid examination, available in 
10 patients, showed diversity of patterns. In dif-
ferent cases the domination of neutrophils [23], 
lymphocytes [20] or eosinophils [22] could be 
seen, but most frequently a mixed pattern was pre-
sent. Not all patients with blood eosinophilia had 
high eosinophil counts in BAL fluid [22, 30, 31], 
and some patients with increased eosinophils in 
BAL fluid had normal eosinophil counts in the 
blood [17–20]. The results of histological exami-
nation of lung biopsy were available for 15 of 27 
reviewed patients. Again, a diversity of patterns 
was present: eosinophilic pneumonia in two pa-
tients [15, 22], organising stage of eosinophilic 
pneumonia with eosinophilic infiltrates in one 
patient [19], features of organising pneumonia 
in five patients [12, 23, 24, 33], non-necrotising 
granulomas and scattered giant cells or giant cells 
alone in three patients [20, 23, 29] and interstitial 
fibrosis in two patients [18, 23]. Only one of our 
patients had histopathological verification. It was 
Patient 1, in whom microscopic examination of 
resected pulmonary nodule revealed organising 
pneumonia with eosinophilic infiltrates. Camus 
et al. [34] noted that organising pneumonia in 
IBD patients differed from cryptogenic organising 
pneumonia by the richer eosinophilic infiltrates, 
independent of taking or not taking medication 
suspected to cause lung injury.
Due to their presentation, typically with 
new-onset dyspnoea, fever, cough, changes in 
chest X-ray and elevated indices of inflamma-
tion, a chest infection was first suspected in our 
patients as well as in the other patients from 
the literature.  As a consequence, an empiri-
cal antibiotic therapy and an effort to identify 
a causative microbiological factor was the first-
-line management. Very rarely in those patients 
cultures yielded a positive result, but even in 
those cases use of proper antibiotics failed to 
bring any improvement. Pulmonary tuberculosis 
is one of the major considerations in these pa-
tients, especially in patients with more insidious 
onset of pulmonary and general symptoms and 
a history of immunosuppressants use. Patient 3, 
with a history of a pulmonary tuberculosis in 
a family member, GCs use in the past and chronic 
breathlessness, sweats and weight loss as pre-
senting symptoms, was a good example of such 
a situation. Diagnostic tests for tuberculosis in 
that patient gave confusing results with negative 
direct microscopic examination of BAL fluid and 
negative blood T-SPOT TB test, on one hand, and 
a positive genetic probe and inconclusive culture 
of BAL fluid, on the other hand.  This patient was 
given treatment with GCs for UC flare, which re-
sulted in a significant improvement of respiratory 
symptoms and radiological picture, which in our 
opinion was clear evidence against tuberculosis. 
In Patient 1, the radiological picture of mul-
tiple masses in the lungs and very high ESR 
aroused concerns about a haematological mali-
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gnancy as a cause. In Patient 2, chest pain and 
triangular-shaped subpleural opacities in the 
chest X-ray as well as an antibiotic failure direc-
ted differential thinking towards a pulmonary 
embolism with pulmonary infarctions. IBD is 
a well-recognised risk factor for thromboembolic 
disease [35–38]. Use of additional diagnostic tools 
such as histopathological examination of lung 
biopsy in one case and pulmonary CT angio-
graphy in the other case, made it relatively easy 
to exclude these conditions. It was more difficult 
to decide whether the pulmonary pathologies 
in our patients developed independently of the 
intestine disease and mesalazine action, or in 
connection with either of them. No conclusive 
proof exists either for a connection between lung 
pathology and IBD, or for a connection between 
lung pathology and mesalazine. Mesalazine to-
gether with its predecessor, sulphasalazine, are 
the main representatives of anti-inflammatory 
agents based on 5-aminisalicylic acid (5-ASA). In 
the German registry [39] 70% of patients with UC 
were treated with those medications. Sulphasa-
lazine is well known for its clinically important 
side effects, which affect up to 20% of users 
and include gastroenterological manifestations, 
hepatic dysfunction, skin rashes, arthralgia 
and fever. The most serious toxicity, however, 
is associated with blood dyscrasias and, less 
frequently, with pulmonary pathology. Parry et 
al. [40] summarised 50 patients reported in the 
literature in the years 1972–1999 as possible 
cases of sulphasalazine-induced lung toxicity. 
Sulphasalazine consists of 5-ASA in conjugation 
with sulphapyridine, and the letter component 
was thought to be responsible for the majority 
of side-effect reactions. Mesalazine, which does 
not contain the sulphur moiety, was introduced 
with hope to reduce systemic side effects and 
allergic reactions. Unfortunately, mesalazine 
appeared to cause adverse effects in around 3% 
of users, mostly headaches, diarrhoea, nausea 
and worsening of the colitis [41]. The incidence 
of mesalazine-induced lung disease is unknown. 
As mentioned above, hypotheses on a connection 
between mesalazine and pulmonary disease are 
based on clinical observations, and those are 
confusing. Evidence in favour of the hypothetical 
toxic effect of mesalazine found in the reviewed 
papers included: 1) continuation of mesalazine 
administration, even in a reduced dose or even 
if GCs were added, caused worsening of clinical 
condition, hypoxaemia, opacities on chest X-ray 
and pulmonary function tests in some patients 
[14, 20, 22, 25, 30, 32]; 2) lymphocytes stimula-
tion test or basophile degranulation test for me-
salazine yielded positive results in some patients 
[13, 19, 28]; 3) clinical and radiologic symp-
toms resolution was observed, usually within 
days or weeks from mesalazine discontinuation 
[13–15, 17–19, 27]; 4) reintroduction of mesa-
lazine caused recurrence of symptoms within 
2 days to 2 weeks in some patients [20, 21, 27]; 
and 5) in some patients with a history of pre-
vious toxicity of sulphasalazine, mesalazine 
caused the same effects [16]. In contrast, ho-
wever, the following arguments question the 
contribution of mesalazine to the development 
of lung pathology: 1) successful reinstitution of 
mesalazine after an episode of its supposed lung 
toxicity in some patients [17, 33]; 2) complete 
resolution of pulmonary problems without me-
salazine cessation or any other action in some 
patients [29, 34], even in patients with positive 
mesalazine lymphocyte stimulation tests [28]; 
and 3) occurrence of clinically, radiologically 
and histopathologically identical pulmonary 
disease in IBD patients not exposed to 5-ami-
nosalicylic acid derivatives [24, 29, 34, 42–48]. 
Blood eosinophilia is considered to be a factor 
suggestive of drug-induced reaction. However, 
there are cases showing that not only blood 
eosinophilia but also BAL eosinophilia and 
even eosinophilic pneumonitis may occur in 
IBD without connection to medications [34]. 
The role of eosinophils in IBD has been noted 
but not fully understood [49].
As our review of the literature showed, pul-
monary disease in IBD patients responded well 
to GCs, but spontaneous regression was seen 
in numerous patients as well. Most commonly 
mesalazine cessation and treatment with GCs 
were applied resulting in a rapid improvement 
[12, 23, 26, 31–33]. This approach was applied 
in Patient 2, in whom mesalazine was stopped 
and GC was commenced. Mesalazine supposito-
ries were withdrawn as well, as there are some 
reports suggesting a relationship between this 
type of mesalazine preparation and lung toxicity 
[50, 51]. Patient 1 decided to continue with mesa-
lazine and declined treatment with GCs. Patient 
3 was treated with GCs and subsequently with 
other immunomodulatory drugs in addition to 
mesalazine, due to IBD activity. In all of them the 
outcome in terms of respiratory system disease 
was good. 
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Conclusions
Pulmonary pathology in the course of IBD 
remains an interesting subject for further inve-
stigation. 
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